Abstract: Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.

Abstract: Systems, methods, lift fans, and aircraft involving active flow control of a ducted fan or fan-in-wing configuration are described.

Abstract: In various embodiments, disclosed herein is a device comprising a non-planar surface, wherein nanostructures are fabricated on the non-planar surface. Also provided herein are methods of making and using a device comprising a non-planar surface, wherein nanostructures are fabricated on the non-planar surface. Further provided herein are methods of using a device comprising one or more non-planar surfaces, wherein the non-planar surfaces comprise one or more microstructures or nanostructures, comprising the steps: (a) using the device for its ordinary purpose; and (b) wherein the microstructures or nanostructures present in the device prevent proliferation of bacteria.

Abstract: An apparatus for a heart of a patient having a cardiac assist device adapted to be implanted into the patient to assist the heart with pumping blood. The apparatus has a sensor adapted to be implanted into the patient. The sensor in communication with the cardiac assist device and the heart which measures native volume of the heart. Alternatively, the sensor monitors the heart based on admittance while the cardiac assist device. Alternatively, the sensor monitors the heart based on impedance.

Abstract: An apparatus for a heart of a patient having a cardiac assist device adapted to be implanted into the patient to assist the heart with pumping blood. The apparatus has a sensor adapted to be implanted into the patient. The sensor in communication with the cardiac assist device and the heart which measures native volume of the heart. Alternatively, the sensor monitors the heart based on admittance while the cardiac assist device. Alternatively, the sensor monitors the heart based on impedance.

Abstract: An apparatus for a heart of a patient having a cardiac assist device adapted to be implanted into the patient to assist the heart with pumping blood. The apparatus has a sensor adapted to be implanted into the patient. The sensor in communication with the cardiac assist device and the heart which measures native volume of the heart. Alternatively, the sensor monitors the heart based on admittance while the cardiac assist device. Alternatively, the sensor monitors the heart based on impedance.

Abstract: A training method for training neural networks to determine a magnetic susceptibility distribution of a sample may include: storing a simulated magnetic susceptibility map of the sample, generating a modified magnetic susceptibility map by combining an influence of one or more external magnetic susceptibility sources with the simulated magnetic susceptibility map and storing the modified magnetic susceptibility maps. The method may include generating a first training image by applying a quantitative susceptibility mapping model the modified magnetic susceptibility map and storing the first training image, applying the first neural network to the first image and a second neural network to an output of the first neural network and changing network parameters of the first and the second neural network depending on a deviation of an output of the second artificial neural network from the simulated magnetic susceptibility map.

Abstract: An apparatus for a heart of a patient having a cardiac assist device adapted to be implanted into the patient to assist the heart with pumping blood. The apparatus has a sensor adapted to be implanted into the patient. The sensor in communication with the cardiac assist device and the heart which measures native volume of the heart. The apparatus has a first cardiac assist device and a second cardiac assist device tuned to maximize blood flow to the body of the patient, while resting the heart so the heart may recover function. Alternatively, the sensor monitors the heart based on admittance while the cardiac assist device. Alternatively, the sensor monitors the heart based on impedance.

Abstract: Kits and methods for diagnosing risk of developing lung cancers and uses thereof are described. In a first aspect, described herein are lung cancer risk test kits that include reagents for measurement of multiple low VAF (defined as VAF<1%) mutants in a set of lung cancer driver genes; and, instructions therefor.

Abstract: The present application generally relates to the development of live attenuated Pneumoviridae strains suitable for use as a vaccine. Particularly, human metapneumovirus (hMPV) ?M2-2 strains (rhMPV-E30M31 and rhMPV-E40L42D44) containing point mutations in a PDZ motif of M2-2, which results in a strain that is both attenuated and immunogenic and, notably, maintains the function of F and G proteins. These live attenuated hMPV strains should be suitable for use in a vaccine capable of providing protection against respiratory infection elicited by hMPV. Additionally, human respiratory syncytial virus (hRSV) strains containing point mutations in a PDZ motif of M2-2 should also be suitable for use as a vaccine capable of providing protection against respiratory infection elicited by hRSV. These Pneumoviridae strains should be useful in vaccines for use in humans and animals, e.g., companion animals and livestock, in treating or providing immunoprotection against respiratory infections.

Abstract: The present invention provides microfabricated substrates and methods of conducting reactions within these substrates. The reactions occur in plugs transported in the flow of a carrier-fluid.

Abstract: Charge mosaic membranes useful for desalination applications, and methods of making and using the same, are described.

Abstract: An apparatus for monitoring a patient post operation having electrically conducting leads which are adapted to extend from inside the patient. The leads having electrodes adapted to communicate with a heart of the patient and apply electrical signals to the heart. The electrodes providing cardiac signals to the computer in response to the electrical signals so the computer can determine in real time at least one of heart volume, end diastolic heart volume, end systolic heart volume, stroke volume, change in heart volume, change in stroke volume, contractility, respiration rate or tidal volume regarding the patient.

Abstract: Provided herein are methods of treating a patient having a cancer that exhibits (i) a hemizygous loss of the TP53 gene; (ii) a hemizygous loss of the POLR2A gene; and/or (iii) a decreased level of expression of a POLR2A gene product relative to a reference (i.e., control) expression level. The methods comprise administering a therapeutically effective amount of a POLR2A inhibitor (e.g., a nucleic acid that inhibits the expression of a POLR2A protein, an amatoxin, alpha-amanitin, or alpha-amanitin conjugated to a cell targeting moiety, such as an EpCAM antibody) to a patient having or determined to have (i) a hemizygous loss of the TP53 gene; (ii) a hemizygous loss of the POLR2A gene; and/or (iii) a decreased level of expression of a POLR2A gene product relative to a reference (i.e., control) level.

Abstract: A process for chemically recycling polyethylene terephthalate (PET) which utilizes a microwave absorber to optimize glycolytic depolymerization of PET via microwave irradiation. The method of chemically degrading PET to its reactive intermediate, bis(2-hydroxyethyl) terephthalate (BHET), is carried out by: (a) combining PET with ethylene glycol and a catalytic system comprising a catalyst and a microwave absorber to produce a heterogeneous reaction mixture; and then (b) heating by microwave irradiating the reaction mixture to a temperature sufficient to produce a reaction product comprising BHET. The BHET monomer then can be purified and re-polymerized to form new, virgin PET.

Abstract: The present invention aims to provide a modified Cas9 protein with relaxed restriction on target sequence while maintaining binding ability to guide RNA, and use thereof. A protein containing the amino acid sequence of SEQ ID NO: 1 in which the 1335-position arginine is mutated into alanine (R1335A), isoleucine (R1335I), methionine (R1335M), threonine (R1335T) or valine (R1335V), the 1111-position leucine is mutated into arginine (L1111R), the 1135-position aspartic acid is mutated into valine (D1135V), the 1218-position glycine is mutated into arginine (G1218R), the 1219-position glutamic acid is mutated into phenylalanine (E1219F), the 1322-position alanine is mutated into arginine (A1322R), and the 1337-position threonine is mutated into arginine (T1337R), and the like.

Abstract: Devices, methods and systems for transmitting signals through a device located in a blood vessel of an animal for stimulating and/or sensing activity of media proximal to the devices. The media can include tissue and/or fluid. A method of controlling an apparatus in communication with a brain machine interface. The method can include measuring a first neural activity in a first neural area and measuring a second neural activity in a second neural area. The first neural activity can be associated with a first intent. The method can include creating and delivering, via the processor, one or more first control signals to the apparatus upon comparing the second neural activity with the first neural activity, and confirming, based on this comparison, that the second neural activity is associated with the first intent.

Abstract: A novel dopant according to the present disclosure includes an anion represented by the following Formula (1) and a counter cation. In Formula (1), R1 and R2 may be each at least one group selected from a nitro group, a cyano group, an acyl group, a carboxyl group, an alkoxycarbonyl group, a haloalkyl group, a sulfo group, an alkylsulfonyl group, an halosulfonyl group, and a haloalkylsulfonyl group, or may be a group formed by R1 and R2 bonded to each other [—SO2-L-SO2—] (where L represents a haloalkylene group). The counter cation may be a radical cation represented by Formula (2), where R1 and R2 represent electron-withdrawing groups that may be bonded to each other to form a heterocycle, and R3 to R5 represent a hydrogen atom, a hydrocarbon group that may have a substituent, or a heterocyclic group that may have a substituent. The dopant is capable of forming an electroconductive composition that shows a high conductivity.

Abstract: A method of making an erythroid cell comprising elevated levels of a target protein or polypeptide, the method comprising: a) provision of an erythroid progenitor which is able to express the target protein or polypeptide; b) expression of the target protein or polypeptide; and c) maturation of the erythroid progenitor into the erythroid cell; wherein during maturation of the erythroid progenitor into the erythroid cell, the target protein or polypeptide is configured and/or inhibited such that ubiquitination of the target protein or polypeptide is hindered or prevented. Erythroid cells, pharmaceutical compositions and methods of use related thereto, and a method of screening for proteins or polypeptides degraded by ubiquitination during maturation of an erythroid progenitor are also provided.

Abstract: A method of manufacturing a composite member including an aluminum member and a resin member bonded to each other, the method including: performing blasting on a surface of the aluminum member; modifying the surface of the aluminum member into aluminum hydroxide, the modifying including causing the surface of the aluminum member having undergone blasting to react with water by using at least one of heat and plasma; and directly bonding the resin member to the surface of the aluminum member modified to the aluminum hydroxide.